ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-OR016

Large-Scale Systemic Proteome Profiling of More Than 5,000 Proteins to Differentiate Primary Glomerular Diseases

Session Information

Category: Artificial Intelligence, Digital Health, and Data Science

  • 300 Artificial Intelligence, Digital Health, and Data Science

Authors

  • Oh, Jae-ik, Seoul National University College of Medicine, Jongno-gu, Seoul, Korea (the Republic of)
  • Jeong, Kyeonghun, Seoul National University, Gwanak-gu, Seoul, Korea (the Republic of)
  • Park, Sehoon, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Cho, Jeongmin, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si, Gyeonggi-do, Korea (the Republic of)
  • Kim, Kwangsoo, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Kim, Dong Ki, Seoul National University College of Medicine, Jongno-gu, Seoul, Korea (the Republic of)
Background

Primary glomerular diseases (GN) require kidney biopsy for definitive diagnosis. We investigated whether systemic plasma proteome profiling with machine learning could enable non-invasive classification of GN subtypes.

Methods

We analyzed 5,416 plasma proteins using Olink Explore HT from a discovery and validation cohort. The discovery cohort included 14 patients with focal segmental glomerulosclerosis (FSGS), 46 with IgA nephropathy (IgAN), 48 with minimal change disease (MCD), 15 with anti-PLA2R antibody-positive membranous nephropathy (MN), and 38 healthy individuals, while the validation cohort included 14 FSGS, 32 IgAN, 15 MCD, and 10 MN patients. To develop models to classify each GN subtype, we trained logistic regression models with elastic net regularization by the discovery set with or without baseline clinical features (eGFR and UPCR), and evaluated performances by the validation set. Gene set enrichment analysis (GSEA) was performed on ranked protein coefficient values to identify associated biological pathways.

Results

Plasma proteome variation showed strong disease-specific patterns independent of eGFR or proteinuria. The model incorporating the top 50 proteins per subtype achieved strong discriminatory power, yielding an overall ROC-AUC of 0.86 in the validation set. Subtype-specific performance was also strong from MCD, MN, and IgAN (Figure 1C). However, performance was relatively lower for FSGS (AUC = 0.69). Notably, including UPCR and eGFR as features in the model did not significantly improve its performance. GSEA revealed enrichment of hemostasis in MCD, humoral immune response in IgAN, lymphocyte activation in FSGS, and regulation of cell differentiation in MN.

Conclusion

Distinct plasma proteome signatures exist for each GN subtype, providing a promising tool for non-invasive diagnosis and disease classification.

Digital Object Identifier (DOI)